Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Oxylan 40mg modified-release tablets (Actavis)
0407020ADBFAIAH
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 5mg modified-release tablets (Actavis)
0407020ADBFAFAK
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 80mg modified-release tablets (Actavis)
0407020ADBFAJAI
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxypertine 10mg capsules
0402010N0AAAAAA
|
Oxypertine | Oxypertine | Central Nervous System | No data available |
|
Oxypertine 40mg tablets
0402010N0AAABAB
|
Oxypertine | Oxypertine | Central Nervous System | No data available |
|
Painex caplets
0407010X0CGAAAD
|
Painex | Paracetamol combined preparations | Central Nervous System | No data available |
|
Paldesic paracetamol 250mg/5ml oral suspension
0407010H0BCACAC
|
Paldesic | Paracetamol | Central Nervous System | No data available |
|
Palfium 10mg tablets
0407020D0BBABAE
|
Palfium | Dextromoramide tartrate | Central Nervous System | No data available |
|
Palfium 5mg tablets
0407020D0BBAAAD
|
Palfium | Dextromoramide tartrate | Central Nervous System | No data available |
|
Paliperidone 150mg/1.5ml inj and Paliperidone 100mg/1ml inj
0402020ABAAAEAE
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | No data available |
|
Palladone 20mg/1ml solution for injection ampoules
040702050BBAIAM
|
Palladone | Hydromorphone hydrochloride | Central Nervous System | No data available |
|
Palladone 2mg/1ml solution for injection ampoules
040702050BBAHAL
|
Palladone | Hydromorphone hydrochloride | Central Nervous System | No data available |
|
Palladone 50mg/1ml solution for injection ampoules
040702050BBAKAP
|
Palladone | Hydromorphone hydrochloride | Central Nervous System | No data available |
|
Palonosetron 250micrograms/5ml solution for injection vials
0406000ABAAAAAA
|
Palonosetron hydrochloride | Palonosetron hydrochloride | Central Nervous System | No data available |
|
Palonosetron 500microgram capsules
0406000ABAAABAB
|
Palonosetron hydrochloride | Palonosetron hydrochloride | Central Nervous System | No data available |
|
Pamergan P100 solution for injection 2ml ampoules
0407020V0BCAAAI
|
Pamergan | Pethidine hydrochloride | Central Nervous System | No data available |
|
Panadol 500mg capsules
0407010H0BFAFAA
|
Panadol (Systemic) | Paracetamol | Central Nervous System | No data available |
|
Panadol 500mg tablets
0407010H0BFADAM
|
Panadol (Systemic) | Paracetamol | Central Nervous System | No data available |
|
Panadol Extra Advance 500mg/65mg tablets
0407010U0BBACAA
|
Panadol Ex | Paracetamol and caffeine | Central Nervous System | No data available |
|
Panadol Extra soluble tablets
0407010U0BBABAC
|
Panadol Ex | Paracetamol and caffeine | Central Nervous System | No data available |
|
Panadol Extra tablets
0407010U0BBAAAA
|
Panadol Ex | Paracetamol and caffeine | Central Nervous System | No data available |
|
Panadol OA 1000mg tablets
0407010H0BFAKDL
|
Panadol (Systemic) | Paracetamol | Central Nervous System | No data available |
|
Panadol Period Pain 500mg/65mg tablets
0407010U0BHAAAA
|
Panadol Period Pain | Paracetamol and caffeine | Central Nervous System | No data available |
|
Panadol Ultra 12.8mg/500mg tablets
0407010F0BIAAAP
|
Panadol Ultra | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | No data available |
|
Papaveretum 15.4mg/1ml solution for injection ampoules
0407020ABAAABAB
|
Papaveretum | Papaveretum | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.